The Incidence of Abemaciclib-induced Interstitial Lung Disease: A Single-center Retrospective Study in Japan.
The incidence of abemaciclib-induced ILD was 20.4%, which was higher than previously reported values. Today, as abemaciclib is one of the standard treatments for ER-positive, HER2-negative breast cancer, we should be more careful about ILD.
Authors
- Masayuki Fujii (ORCID: https://orcid.org/0000-0002-4798-3943)
- Suya Hori
- Takeshi Hashimoto (ORCID: https://orcid.org/0000-0002-1157-4101)
- Yoko Sakoda
- Teruaki Nishiuma (ORCID: https://orcid.org/0000-0001-9390-8031)
- Masato Taki
- Haruna Nakamura (ORCID: https://orcid.org/0009-0009-2230-8958)
- S. Tokunaga (ORCID: https://orcid.org/0000-0002-1613-9950)
- Mitsutoshi Ogino
- Kazuhiko Tsuchiya
Institutions
- Kagawa Prefectural Central Hospital (JP)
- Kobe University (JP)
Publication Details
- Journal
- PubMed
- Published
- 2025-08-07
- DOI
- https://doi.org/10.24546/0100497175
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00